Retatrutide (20 mg) is a synthetic peptide designed to engage glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It includes an aminoisobutyric acid (Aib) substitution and a lipid side chain to enhance stability and receptor interaction.

With a molecular weight of 4731.33 g/mol and the chemical formula C₂₂₁H₃₄₂N₄₆O₆₈, Retatrutide is studied to understand its effects on metabolic regulation in controlled models. It is supplied as a lyophilized powder in a 20 mg vial, confirmed for identity and purity via HPLC and mass spectrometry.

Retatrutide (20 mg) Key Features & Specs

• Subcategory: Weight Loss & Metabolic Peptides
• Strength: 20 mg
• CAS: 2381089-83-2
• Chemical Formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular Weight: 4731.33 g/mol
• Peptide Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ (Sodium salt)
• Synonyms: Retatrutide acetate, LY3437943

For laboratory research use only.

Retatrutide (20 mg) Research Uses

Retatrutide is studied for its simultaneous activation of GLP-1, GIP, and glucagon receptors, making it useful for exploring metabolic processes, glucose regulation, and energy balance.

Research has focused on:

• Appetite Regulation: The GLP-1 pathway’s role in satiety signaling and glycemic control.
• Lipid Metabolism: GIP and glucagon receptor activation in lipid metabolism and energy balance.
• Obesity and Metabolic Dysfunction: Its effect on obesity, insulin resistance, and metabolic dysfunction.
• Liver Fat Content: Research on its effects in steatotic liver disease models.
• Gastric Emptying and Nutrient Absorption: Impact on digestion and absorption processes.

Retatrutide (20 mg) Insights & Observed Findings

Preclinical and clinical research studies have reported a range of dosing strategies; all findings below are experimental and should not be interpreted as established clinical outcomes.

In preclinical studies, retatrutide has been administered at doses around 10 nmol/kg, typically over periods ranging from several days to weeks. Findings include dose-dependent changes in body weight, food intake, and metabolic markers. Observed changes in liver fat content and shifts in inflammatory and fibrotic markers in hepatic tissue have also been reported.

In human clinical research, once-weekly dosing regimens ranging from 0.5 mg to 12 mg have been evaluated. These studies have reported measurable, dose-related changes in body weight, glycemic markers, and cardiometabolic parameters over periods ranging from several weeks to several months.

Further findings include gastrointestinal responses such as nausea and changes in bowel patterns, which are monitored in metabolic peptide research. Pharmacokinetic data suggest an extended half-life, consistent with less frequent administration intervals in research protocols.

Substudies on liver health using imaging techniques have shown measurable changes in liver fat percentages over time, with variation observed across dosing levels. Variation in outcomes across dose levels was reported, with differences observed in measured endpoints across study populations. Ongoing research explores the long-term effects and broader implications of this compound.

Retatrutide (20 mg) Handling & Storage

• Store Retatrutide (20 mg) at approximately –20°C in a dry, controlled laboratory environment. Protect from light and moisture to maintain peptide integrity.
• Before opening, allow the vial to reach room temperature to reduce condensation.
• For reconstitution, dissolve the peptide in a sterile buffer or a suitable solvent, as specified in the experimental protocol. Mix gently until fully dissolved.
• Reconstituted solutions intended for experimental work should be stored at 2–8°C and protected from light.
• Laboratories should follow validated handling procedures based on experimental requirements.

Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
4. Ma J, Hu X, Zhang W, Tao M, Wang M, Lu W. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. Endocrine. 2025;87(1):159-169. doi:10.1007/s12020-024-03998-8